Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant Phase 1 in ER+/HER2- Breast Cancer
NCT02338349Phase 1Completed
- Sponsor
- Stemline Therapeutics
- Start
- Jan 2015
- Primary completion
- Sep 2019
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elacestrant in breast cancer, sponsored by Stemline Therapeutics. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Jan 2015; status: completed.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02338349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338349.